Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference
2024年5月24日 - 5:05AM
ビジネスワイヤ(英語)
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage
biopharmaceutical company focused on developing and commercializing
novel therapies for rare endocrine disorders with significant unmet
medical need, today announced that Javier Szwarcberg, M.D., M.P.H.,
Chief Executive Officer, will present at the Jefferies Global
Healthcare Conference on June 5, 2024, at 5:00 p.m. ET.
Interested parties can access the live webcast here. An archived
copy of the webcast will be available on the events section of the
company’s investor relations website for approximately 90 days.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company
focused on developing and commercializing novel therapies for rare
endocrine disorders with significant unmet medical need. Spruce is
initially developing its wholly-owned product candidate,
tildacerfont, as the potential first non-steroidal, once-daily
therapy for patients suffering from classic congenital adrenal
hyperplasia (CAH) and other endocrine disorders. To learn more,
visit www.sprucebio.com and follow us on X, LinkedIn, Facebook, and
YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240522135392/en/
Media Contact Katie Beach Oltsik Inizio Evoke Comms (937)
232-4889 Katherine.Beach@inizioevoke.com media@sprucebio.com
Investors Samir Gharib President and CFO Spruce
Biosciences, Inc. investors@sprucebio.com
Spruce Biosciences (NASDAQ:SPRB)
過去 株価チャート
から 5 2024 まで 6 2024
Spruce Biosciences (NASDAQ:SPRB)
過去 株価チャート
から 6 2023 まで 6 2024